OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 150,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $220,500.00. Following the completion of the transaction, the chief executive officer now directly owns 213,186,477 shares in the company, valued at $313,384,121.19. This represents a 0.07 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.48 per share, with a total value of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost acquired 125,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.56 per share, for a total transaction of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The stock was purchased at an average price of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was bought at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock. The stock was purchased at an average cost of $1.50 per share, with a total value of $420,274.50.

OPKO Health Price Performance

OPKO Health stock opened at $1.47 on Friday. The company’s 50 day simple moving average is $1.54 and its 200-day simple moving average is $1.51. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a 1 year low of $0.86 and a 1 year high of $1.76. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.63.

Institutional Trading of OPKO Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OPK. Rubric Capital Management LP increased its stake in OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after purchasing an additional 4,284,336 shares during the period. Barclays PLC increased its stake in OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after buying an additional 329,870 shares during the period. Assenagon Asset Management S.A. lifted its holdings in OPKO Health by 142.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after buying an additional 876,272 shares in the last quarter. Squarepoint Ops LLC purchased a new position in OPKO Health in the 2nd quarter valued at approximately $592,000. Finally, BNP Paribas Financial Markets grew its stake in shares of OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after acquiring an additional 217,450 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on OPK. Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Wednesday, January 8th. Finally, StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.